- Resverlogix Corp. (RVX) announced the publication of an article in the American Journal of Respiratory and Critical Care Medicine
- The article outlines the positive impact of apabetalone in an investigator-led pulmonary arterial hypertension (PAH) pilot study
- All patients completed the 16-week trial without discontinuation or dose reduction, suggesting that apabetalone was well tolerated
- Going forward, full trial results will be presented at an upcoming scientific meeting (to be determined)
- Resverlogix Corp. (RVX) is up 8.70 per cent, trading at C$0.50 at 10:29 am ET
Resverlogix Corp. (RVX) announced the publication of an article in the American Journal of Respiratory and Critical Care Medicine.
The article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p.
“The encouraging results published today highlight the potential benefit of BET protein inhibition, such as Resverlogix’s apabetalone, as a therapeutic strategy for PAH,” said Dr. Steeve Provencher, Director of Pulmonary Research, Québec Heart and Lung Institute, Laval University, and the lead author of the article.
“We are excited to be moving forward with a larger trial of apabetalone in PAH patients,” added Dr. Provencher.
Some of the publication highlights include how all patients completed the 16-week trial without discontinuation or dose reduction, suggesting that apabetalone was well tolerated in the study population.
Patients treated with apabetalone exhibited a reduction in pulmonary vascular resistance (PVR) at 16 weeks, the critical exploratory efficacy endpoint of the study.
Apabetalone treatment was also associated with improved cardiac output (CO) and stroke volume (SV) over the 16-week treatment course.
“The APPRoAcH pilot study showed the potential benefit apabetalone can offer PAH patients,” said Donald J. McCaffrey, President & CEO of Resverlogix.
Full trial results will be presented at an upcoming scientific meeting (to be determined).
The encouraging results of this study pave the way for the larger multi-centred APPRoAcH-2 trial.
This is expected to begin enrolling patients later this year and will be a phase 2, randomized, placebo-controlled study of apabetalone for the treatment of PAH.
Apabetalone (RVX-208) is a first-in-class, small molecule therapeutic candidate with an epigenetic mechanism of action.
It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that prevents and treats disease progression by regulating the expression of disease-causing genes.
Due to the extensive role of BET proteins in the human body, apabetalone can simultaneously target multiple disease-related biological processes while maintaining a well-described safety profile – leading to a new way to treat chronic disease.
Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, to develop first-in-class therapies for patients with chronic disease.
Resverlogix Corp. (RVX) is up 8.70 per cent, trading at C$0.50 at 10:29 am ET.
